Related Experiment Video
Updated: Nov 21, 2025
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Effect of Danhong Injection () on Improving Coronary Microcirculation Injury after Percutaneous Coronary Intervention
Qing-Rong Liu1,2,3, Hong-Xu Liu4, Wen-Long Xing4
1Department of Cardiology, Fuwai Hospital of Chinese Academy of Medical Sciences, Beijing, 100037, China.
Insights
Danhong Injection effectively improves coronary microcirculation injury after percutaneous coronary intervention (PCI), showing non-inferiority to statin therapy. This treatment offers a viable option for enhancing outcomes in coronary heart disease (CHD) patients post-PCI.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Percutaneous coronary intervention (PCI) can lead to microcirculatory injury in patients with coronary heart disease (CHD).
- Effective management of post-PCI microcirculation is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of Danhong Injection in improving microcirculatory injury following PCI.
- To compare Danhong Injection with intensive statin therapy and standard care.
Main Methods:
- A randomized controlled trial involving 90 CHD patients with post-PCI microcirculatory injury.
- Patients were randomized into three groups: Danhong Injection, intensive statin therapy, or standard statin therapy.
- Index of Microcirculation Resistance (IMR) was measured to assess microcirculatory injury before and after treatment.
Main Results:
- Both Danhong Injection and intensive statin groups showed significant reductions in IMR compared to the control group (P<0.01).
- No significant difference in IMR was observed between the Danhong Injection group and the intensive statin group (P=0.080).
Conclusions:
- Danhong Injection demonstrates non-inferior efficacy compared to intensive statin therapy in improving coronary microcirculation post-PCI.
- Early administration of Danhong Injection is an effective strategy for managing microcirculatory injury after PCI in CHD patients.
Objective:
To explore the effectiveness of Danhong Injection () on improving microcirculatory injury after percutaneous coronary intervention (PCI) in patients with coronary heart disease (CHD).
Methods:
A randomized controlled trial was conducted and 90 patients were enrolled. A random sequence was generated using statistical analysis software. Patients with microcirculatory injuries after PCI were randomly divided into 3 groups for treatment (30 subjects in each group): Danhong Injection group: after PCI, Danghong Injections were given with intravenous administration with 40 mL twice a day for a week; statins intensive group: after PCI, atorvastatin calcium tablets were given oral medication with 80 mg once, and then atorvastatin 40 mg daily for 1 week; the control group: after PCI, atorvastatin calcium tablets were given oral medication with 10-20 mg daily for 1 week. The index of microcirculation resistance (IMR) was used to assess microcirculatory injury during PCI. The IMR of the target vessel was reexamined after 1 week of drug treatment.
Results:
After one week's drug treatment, IMR was significantly decreased in both statins intensive group and Danhong Injection group compared with the control group (P<0.01), but no difference was found between statins intensive group and Danhong injection group (14.03 ± 2.54 vs. 16.03 ± 5.72 U, P=0.080).
Conclusions:
The efficacy of Danhong Injection is non-inferior to statin. Early use of Danhong Injection after PCI can effectively improve coronary microcirculation injury after PCI.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care